Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16883 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Michihiro Hide und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Bradykinin B2 Receptor Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited, Japan, Takeda Pharmaceutical Company.
Abstract (Originalsprache)
We evaluated the safety, efficacy, and pharmacokinetics of subcutaneous weight‐adjusted icatibant for the treatment of acute hereditary angioedema attacks in Japanese pediatric patients. Two patients (aged 10–13 and 6–9 years) received icatibant for a total of four attacks. Each attack was abdominal and/or cutaneous and was treated with a single icatibant injection. Mild or moderate injection‐site reactions were the only adverse events reported. Time to onset of symptom relief was 0.9–1.0 h. Icatibant was rapidly absorbed, with a pharmacokinetic profile consistent with previous studies. Simulated exposure levels were consistent with non‐Japanese pediatric patients. These results support the safety and efficacy of icatibant in Japanese pediatric patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.
- Department of Dermatology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
- Quantitative Clinical Pharmacology, Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.
- PRA Development Center KK, Osaka, Japan.
- Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.
ORCID-Profile: Michihiro Hide, Kazuyuki Ishida
Förderung
- Takeda Pharmaceutical Company Limited, Japan
- Takeda Pharmaceutical Company
Zitieren
APA
Hide, M., Wang, Y., Dote, N., Miyakawa, K., Sugiura, K., & Ishida, K. (2023). Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16883
Vancouver
Hide M, Wang Y, Dote N, Miyakawa K, Sugiura K, Ishida K. Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16883
BibTeX
@article{Hide2023,
author = {Hide, Michihiro and Wang, Yi and Dote, Nobuhito and Miyakawa, Kou and Sugiura, Kenkichi and Ishida, Kazuyuki},
title = {Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16883}
}
EUVIMED